GlassScriptPhysician profile
Casey Overturf
NPI 1114305935
$6,154.40
in general payments reported to CMS, 2019-2025
29 companies · $931 in 2025
The $931 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,562 · 2022: $580 · 2023: $1,447 · 2024: $1,633 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,613 · Education: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,613.43 |
| Education | $398.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,183.58 | 2021-2025 | Tremfya, Remicade, Stelara |
| Regeneron Healthcare Solutions, INC. | $611.01 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $555.91 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $458.39 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Abbvie INC. | $448.14 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $418.61 | 2023-2025 | Sotyktu |
| Pfizer INC. | $379.49 | 2021-2025 | |
| Ucb, INC. | $272.50 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $225.38 | 2021-2025 | Taltz, Ebglyss |
| Epi Health, LLC | $173.74 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $171.41 | 2021-2022 | |
| Incyte Corporation | $169.97 | 2021-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $148.61 | 2023-2024 | Zoryve |
| Genzyme Corporation | $142.77 | 2021-2025 | |
| Leo Pharma INC. | $141.27 | 2021-2024 | Adbry |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $137.75 | 2023-2024 | Vtama |
| Amgen INC. | $88.05 | 2021-2024 | Otezla |
| Almirall LLC | $82.97 | 2021-2022 | |
| Galderma Laboratories, L.P. | $76.70 | 2024-2025 | Nemluvio |
| Organon LLC | $53.62 | 2025 | Vtama |
| Journey Medical Corporation | $42.01 | 2021 | |
| Verrica Pharmaceuticals INC. | $41.65 | 2024-2025 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $29.51 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.97 | 2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $21.84 | 2021 | |
| Genentech USA, INC. | $16.05 | 2023 | Erivedge |
| Kerecis Limited | $15.32 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Mimedx Group, INC. | $13.88 | 2025 | |
| Mayne Pharma Commercial LLC | $11.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Overturf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.